Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP-CMV in Pediatric High-grade Glioma, DIPG, and Recurrent Medulloblastoma
NCT05096481Phase 2Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2028
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PEP-CMV in glioma, diffuse intrinsic pontine glioma (DIPG), medulloblastoma, sponsored by Nationwide Children's Hospital. Started Jul 2024; status: recruiting.
02
Drugs
PEP-CMV
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)medulloblastoma
Beyond the preview
Go deeper on NCT05096481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05096481.